Results 141 to 150 of about 3,242,366 (329)

Associations of cardiovascular–kidney–metabolic syndrome stages with premature mortality and the role of social determinants of health

The Journal of Nutrition, Health & Aging
Highlights • Cardiovascular–kidney–metabolic (CKM) stages 3–4, but not stages 1–2, had higher premature mortality.• Unfavorable social determinants of health were related to higher premature mortality across CKM stages.• There were sex and age ...
Rui-Xin Zhu, Ran Wang, Jing-Jing He, Lang-Run Wang, Hui-Yu Chen, Yi-Fan Wang, Peng An, Ke-Ji Li, Fa-Zheng Ren, Wei-Li Xu, J. A. Martinez, A. Raben, Jie Guo   +12 more
semanticscholar   +1 more source

Safety outcomes of antidiabetic medications: A comprehensive review of the EU summaries of product characteristics and international clinical practice guidelines

British Journal of Clinical Pharmacology, EarlyView.
Aims Information on the safety profile of antidiabetic medications is essential for informed treatment decisions in type 2 diabetes mellitus. Although this information is available in regulatory documents of individual drugs, a comprehensive overview across all approved antidiabetics is lacking.
David Liang, Daniala L. Weir, Safana Thevasahayam, Vera H. M. Deneer, Arno Siebes, Helga Gardarsdottir   +5 more
wiley   +1 more source

Cardiovascular-Kidney-Metabolic Syndrome: An Update for Clinician

Jurnal Penyakit Dalam Indonesia
Cardiovascular-kidney-metabolic (CKM) syndrome is a systemic abnormality resulting from complex pathophysiological interactions among cardiovascular disease, chronic kidney disease, and metabolic risk factors, particularly diabetes mellitus and obesity ...
Muhammad Yamin, Harits Adi Putra
doaj   +1 more source

Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome

Future Cardiology
Recent trials underscore the cardiovascular (CV), renal, and metabolic benefits of semaglutide in individuals with and without type 2 diabetes (T2D). In T2D, semaglutide enhances glycemic control, reduces major adverse CV events (MACE), and slows chronic kidney disease (CKD) progression.
openaire   +2 more sources

Hypertension in obesity: A focus on individualized pharmacotherapy and the role of body composition, on behalf of the European Society of Hypertension Working Group on Diabetes and Metabolic Risk Factors and Working Group on Lifestyle, Cardiovascular Pharmacotherapy and Adherence

British Journal of Clinical Pharmacology, EarlyView.
Hypertension in obesity represents a major global health challenge, closely linked to the global epidemics of obesity, type 2 diabetes and metabolic dysfunction. Excess adiposity contributes to elevated blood pressure through multiple, interrelated mechanisms, including activation of the renin–angiotensin–aldosterone system, sympathetic nervous system ...
Christina Antza, Andrej Belancic, Jens Jordan, Alberto Esteban, Anna Oliveras, Ryan McNally, Panagiota Anyfanti, Jorie Versmissen, María S. Fernández‐Alfonso, Vasilios Kotsis, Thomas Weber, Alexandre Persu, Reinhold Kreutz   +12 more
wiley   +1 more source

Selected Parameters Which Support the Laboratory Diagnosis of Cardiovascular-Kidney-Metabolic Syndrome in the Light of Current Guidelines: A Narrative Review

Progression in understanding the relationships among cardiovascular, kidney, and metabolic diseases necessitates reappraising these concepts. Here, this narrative review explains the evolution of the ideas behind cardiovascular-kidney-metabolic syndrome (
Violetta Sulżyc-Bielicka, Robert Nowak, Jeremy S. C. Clark, Bugajska, Justyna, Clark, Jeremy S. C., Sul\u17cyc-Bielicka, Violetta, Michał Sławiński, Andrzej Brodkiewicz, Justyna Bugajska, Brodkiewicz, Andrzej, S\u142awi\u144ski, Micha\u142, D\u105browska, Katarzyna, Kostrzewa-Nowak, Dorota, Nowak, Robert, R\uf3\u17ca\u144ski, Jacek, Jacek Różański, Dorota Kostrzewa-Nowak, Katarzyna Dąbrowska   +17 more
core   +1 more source

Waist Circumference predicting Cardiovascular Disease in Korean Men and Women [PDF]

, 2010
Objective: Obesity and cardiovascular disease (CVD) are closely related and have become increasingly prevalent in Korea. Asians are more prone to obesity-related co-morbidities than Caucasians, even at lower body mass index (BMI) and/or smaller waist ...
Sun Ha Jee, Sat Byul Park
core  

Increased Prevalence of Metabolic Syndrome in Patients with Psoriatic Arthritis

, 2014
Objective: The increased incidence of cardiovascular disease (CVD) in patients with psoriatic arthritis (PsA) has been reported previously. We aimed to evaluate the presence of metabolic syndrome and to assess the insulin resistance associated with ...
Bahadir, Cengiz, Pehlevan, Yekta, Pehlevan, Seval, Goktay, Fatih, Ince, Nurhan, Yetkin, Demet Ozgil, Kayatas, Kadir   +6 more
core   +1 more source

SGLT2 Inhibitors and GLP-1 Receptor Agonists in Cardiovascular–Kidney–Metabolic Syndrome

Biomedicines
Cardiovascular–Kidney–Metabolic (CKM) syndrome symbolizes a single pathophysiologic entity including obesity, type 2 diabetes, chronic kidney disease, and cardiovascular disease.
Aryan Gajjar, Arvind Kumar Raju, A. Gajjar, Mythili Menon, S. Shah, S. Dani, Andrew Weinberg   +6 more
semanticscholar   +1 more source

Novel Cardiometabolic Medications in the Cardiovascular-Kidney-Metabolic Syndrome Era

The Journal of Clinical Endocrinology & Metabolism
Abstract Cardiovascular-kidney-metabolic (CKM) syndrome represents a complex interplay of obesity, hypertension, hyperlipidemia, type 2 diabetes mellitus, chronic kidney disease, and cardiovascular disease, driving elevated morbidity and mortality.
Neal Pohlman, Prem N Patel, Utibe R Essien, Jasmyn J Tang, Joshua J Joseph   +4 more
openaire   +2 more sources